EPAM Systems, Inc. <EPAM.N>: Mizuho Cuts Target Price to $130 From $162
EPAM•Related News

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile
ABCL•

DocGo delays filing quarterly report for period ended June 30, 2026
DCGO•

ConocoPhillips <COP.N>: Truist Securities raises target price to $130 from $115
COP•

Ziff Davis Inc <ZD.O>: Susquehanna Raises Target Price to $75 From $60
ZD•

L.B. Foster profit rises on higher gross margin
FSTR•